(Total Views: 232)
Posted On: 10/15/2025 5:27:16 PM
Post# of 158000
In the years following the completion of thios study, the field of MASH has significantly changed/advanced.
In 2024, Resmitirom was approved, and in Aug 2025, the GLP-1receptor agonist Semaglutide was approved to treat patients with F2/3 MASH.
Numerous additional compounds are now in Phase 3 after demonstrating impressive histolic efficacy, Thus, the trend towards improvement in steatosis due to Leronlimab, as demonstrated in this study should be considered in this context when deciding whether or not to further explore this compound as MONOtheraphy... or as part of combination therapy in patients with MASH with fibrosis or for other fibrosis indications.
In 2024, Resmitirom was approved, and in Aug 2025, the GLP-1receptor agonist Semaglutide was approved to treat patients with F2/3 MASH.
Numerous additional compounds are now in Phase 3 after demonstrating impressive histolic efficacy, Thus, the trend towards improvement in steatosis due to Leronlimab, as demonstrated in this study should be considered in this context when deciding whether or not to further explore this compound as MONOtheraphy... or as part of combination therapy in patients with MASH with fibrosis or for other fibrosis indications.
(4)
(0)
